Colleen Gray - 07 Oct 2025 Form 4 Insider Report for Monogram Technologies Inc. (MGRM)

Reporting relationship: Director
Issuer ticker: MGRM
Reported as of: 07 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Oct 2025, 21:59:13 UTC
Prior SEC filing: 14 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Benjamin Sexson, as Attorney-in-Fact for Colleen Gray

Key filing fact

Colleen Gray filed Form 4 for Monogram Technologies Inc. (MGRM) on 14 Oct 2025.

Key facts

This page summarizes Colleen Gray's Form 4 filing for Monogram Technologies Inc. (MGRM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Oct 2025, 21:59.

Change

Previous filing in this sequence was filed on 14 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002091035 Primary reporting owner

Gray Colleen

Relationship: Director
Address: 3913 TODD LANE, AUSTIN
Signature: /s/ Benjamin Sexson, as Attorney-in-Fact for Colleen Gray
Signature date: 14 Oct 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MGRM transaction Derivative

Stock Option

Disposed to Issuer

Transaction value
Shares: -8,000
Change %: -100%
Price
Shares after: 0
Date: 07 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,000
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Colleen Gray is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

In connection with the terms of an Agreement and Plan of Merger, dated July 11, 2025 (the "Original Merger Agreement"), by and among the Issuer, Zimmer Biomet Holdings, Inc., ("Zimmer Biomet"), and Honey Badger Merger Sub, Inc., a wholly owned subsidiary of Zimmer Biomet ("Merger Sub"), as amended by that certain First Amendment to Agreement and Plan of Merger, dated August 27, 2025, by and between the Issuer and Zimmer Biomet (together with the Original Merger Agreement, the "Merger Agreement"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Zimmer Biomet upon consummation of the merger (the "Effective Time").

Footnote F2

At the Effective Time, each outstanding and unexercised option, whether or not vested, was cancelled and converted into the right to receive, (i) a cash payment equal to the excess of (A) $4.04 (the "Cash Amount") over (B) the exercise price per share of such option, and (ii) one contractual contingent value right issued pursuant to and in accordance with the CVR agreement ("CVR"). However, any such option (1) with a per share exercise price that is equal to or greater than the Cash Amount but less than the sum of the Cash Amount and the maximum CVR consideration payable pursuant to the CVR agreement (that is, $16.41) was cancelled and converted into the right to receive, for each share of common stock underlying such option, one CVR issued pursuant to and in accordance with the CVR agreement less the Cash Amount and (2) with a per share exercise price greater than $16.41 was cancelled for no consideration.